Bayer And Regeneron Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3